Medication info
Lokan Duo Tablets 5/8 mg

Lokan Duo Tablets 5/8 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
AlboGen Korea Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 201702397 · Approved 2017.05.16 · Insurance code 652606340

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the risk of atherosclerosis and cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
Candesartan cilexetil, essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Candesartan cilexetil, heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
AlboGen Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the risk of atherosclerosis and cardiovascular disease

  • Essential hypertension
  • impaired left ventricular systolic function
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • risk factors for coronary artery disease
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medication is suitable for patients who require the combined use of two drugs, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is mainly used for patients with essential hypertension and heart failure with decreased left ventricular systolic function (especially when additional treatment is needed or when tolerance to ACE inhibitors is reduced). Rosuvastatin is prescribed for patients with hypercholesterolemia and dyslipidemia when dietary therapy and exercise are difficult to control or need supplementation. Additionally, it helps in the treatment of homozygous familial hypercholesterolemia or to slow the progression of atherosclerosis. For adult patients at risk of cardiovascular disease, it is used to reduce the risk of stroke, myocardial infarction, and revascularization. By administering these two drugs together, blood pressure and blood lipid levels can be effectively controlled, improving cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

Candesartan cilexetil, essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Candesartan cilexetil, heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Use is contraindicated in individuals with hypersensitivity to this medication, liver disease, severe liver dysfunction, kidney failure, pregnant or breastfeeding women, and certain genetically predisposed lactose intolerant patients. Elderly patients, those with hyperkalemia, and patients with mild to moderate liver dysfunction should use this medication cautiously, especially if experiencing symptoms of myalgia or myopathy, in which case immediate consultation with healthcare professionals is necessary. This medication may cause muscle-related side effects, so muscle enzyme levels should be tested before and during use, and any symptoms of myalgia or weakness should be reported to a physician immediately. Liver function abnormalities may occur, so periodic checking of liver enzyme levels is necessary, and the medication should be discontinued if liver function deteriorates significantly. This medication may interact with other drugs, so patients should inform healthcare professionals about any other medications they are taking, particularly if using potassium-sparing diuretics, lithium, or nonsteroidal anti-inflammatory drugs. Women who may become pregnant should use appropriate contraception, and nursing mothers are advised to avoid using this medication. Safety and efficacy have not been established for children, and it is not recommended for use. In case of overdose, symptoms such as low blood pressure and dizziness may occur, necessitating immediate medical attention. Dizziness or fatigue may occur while taking this medication, so patients should be cautious when driving or operating machinery. This medication should be kept out of the reach of children, and it is not recommended to transfer the medicine to another container.

Side effects

Headache, nasopharyngitis, localized infections, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, hyperglycemia, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, positional dizziness, miliaria, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, hyperglycemia, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, angioedema, jaundice, hepatitis, liver dysfunction, thrombocytopenia, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness, syncope, facial flushing, weight gain, facial edema, polydipsia, sleep disorders, decreased libido, forgetfulness, appetite loss, increased appetite, tinnitus, taste disturbance, erectile dysfunction, dizziness, hypotension, hyperkalemia, kidney function impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, elevated AST, increased γ-GTP, hepatitis, jaundice, angioedema, increased blood pressure, cerebral infarction, spondylitic myelopathy, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, worsening hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, weakness, fever, paresthesia, dyspepsia, gastroenteritis, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, dyspnea, rash, increased sweating, hematuria, intestinal vascular edema, nausea, diarrhea, increased liver enzyme levels, hepatitis, jaundice, rash, urticaria, itching, angioedema, myalgia, weakness, elevated creatine kinase, increased serum and urinary myoglobin, rhabdomyolysis, arthralgia, myalgia, low back pain, kidney function impairment, acute kidney failure, interstitial pneumonia, shock, syncope, loss of consciousness, thrombocytopenia, acute kidney failure, oliguria, increased serum creatinine, constipation, elevated AST, numbness, sensory disturbance, chest discomfort, abdominal pain, abdominal distension, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and light. Additionally, it is important to store it at a temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.